| |
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates.Register Now!
|
|
Today’s Big NewsJul 29, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Save up to $500 with Early Bird Rates. Register Now!
|
|
| By James Waldron Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view. |
|
|
|
By James Waldron Boehringer Ingelheim is paying up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece” of its immune-oncology portfolio. |
By Annalee Armstrong With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally. |
Sponsored by InMed Pharmaceuticals InMed Pharmaceuticals recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s disease. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now.
|
|
By Nick Paul Taylor Cognition Therapeutics’ phase 2 SHINE trial has taken some of the luster off the Alzheimer’s disease drug candidate CT1812. The oral sigma-2 antagonist failed to statistically beat placebo—or clear Cognition’s own bar for success—on the main efficacy endpoint that focused on symptom severity, but the biotech wants to forge ahead. |
By Annalee Armstrong NewAmsterdam Pharma’s drug reduced cholesterol in patients with a genetic disorder by 41% at Week 52, confirming the therapy’s efficacy but falling outside of the previous range shown in an earlier phase 2 study. |
By James Waldron The FDA has placed vTv Therapeutics’ phase 3 trial for cadisegliatin on hold more than two years after the biotech stacked its remaining chips on the Type 1 diabetes drug. |
By Annalee Armstrong Ventyx Biosciences’ Crohn’s disease medicine did not help patients achieve remission in a phase 2 trial, sending the California biotech’s shares down 20% in pre-market trading Monday morning. |
By Fraiser Kansteiner Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. |
By Eric Sagonowsky After a prior skirmish over tax policy in England, AstraZeneca is now butting heads with officials in the country over innovative drug access. |
By Conor Hale In the game of moneyed musical chairs, it’s clear the tempo has slowed. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. |
|
|---|
|
|
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
